Format

Send to

Choose Destination
Cell. 2012 Feb 3;148(3):409-20. doi: 10.1016/j.cell.2012.01.014.

The genetic basis for cancer treatment decisions.

Author information

1
Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.

Abstract

Personalized cancer medicine is based on increased knowledge of the cancer mutation repertoire and availability of agents that target altered genes or pathways. Given advances in cancer genetics, technology, and therapeutics development, the timing is right to develop a clinical trial and research framework to move future clinical decisions from heuristic to evidence-based decisions. Although the challenges of integrating genomic testing into cancer treatment decision making are wide-ranging and complex, there is a scientific and ethical imperative to realize the benefits of personalized cancer medicine, given the overwhelming burden of cancer and the unprecedented opportunities for advancements in outcomes for patients.

PMID:
22304912
DOI:
10.1016/j.cell.2012.01.014
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center